This study assessed the safety and effectiveness of the new 'vanza triple' in people with CF ages 12 and older who haveat least one gene variant, including F508del, that is responsive to triple combination therapies like Kaftrio. The results of this study show that this new therapy is at least as good at Kaftrio in improving lung function and it is better in reducing sweat chloride levels.